AI Portfolio Summary
In 2025 Q4, DEERFIELD MANAGEMENT COMPANY, L.P. maintained a portfolio of 184 distinct positions. The most significant new addition to the portfolio was BROOKDALE SR LIVING , which now represents 5.46% of the total fund value. The fund also reduced its exposure to INDIVIOR PLC by 51.4%.
Total Positions
184
Quarter
2025 Q4
Top Holding
NUVL (22.2%)
Top 10 Concentration
52.3%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 184
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NUVL
NUVALENT INC
|
Healthcare | 22.16% | 23.75% |
#1
Prev: #1
|
6.5 | -742,574 | -4.1% |
P
S
|
17,248,450 | $1,735,021,586 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
BROOKDALE SR LI...
|
—
|
Bond/Debt | 5.46% | — |
#2
Prev: #—
|
7.2 | 306,885,000 | no change |
NEW
|
306,885,000 | $427,493,874 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 4.10% | 1.98% |
#3
7
Prev: #10
|
3.1 | -9,215 | -0.1% |
P
S
|
9,043,903 | $321,239,435 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 3.40% | 0.68% |
#4
32
Prev: #36
|
3.9 | 62,500 | 7.4% |
P
S
|
903,351 | $266,253,674 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNC
CENTENE CORP DE...
|
Healthcare | 3.39% | 4.93% |
#5
3
Prev: #2
|
1.9 | -2,598,002 | -28.7% |
P
S
|
6,447,998 | $265,335,118 | 2005 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VTRS
VIATRIS INC
|
Healthcare | 3.21% | 3.64% |
#6
2
Prev: #4
|
1.8 | -3,892,913 | -16.2% |
P
S
|
20,206,170 | $251,566,817 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 2.94% | 2.60% |
#7
1
Prev: #6
|
1.2 | -755,729 | -20.7% |
P
S
|
2,894,613 | $230,555,925 | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UTHR
UNITED THERAPEU...
|
Healthcare | 2.65% | 2.73% |
#8
3
Prev: #5
|
2.1 | no change | no change |
P
S
|
425,993 | $207,565,089 | 2007 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 2.63% | 1.62% |
#9
4
Prev: #13
|
3.1 | 418,538 | 11.5% |
P
S
|
4,059,695 | $205,582,955 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
MIRUM PHARMACEU...
|
—
|
Bond/Debt | 2.31% | 2.57% |
#10
2
Prev: #8
|
1.9 | no change | no change |
P
S
|
70,000,000 | $180,707,800 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
CELC
CELCUITY INC
|
Healthcare | 2.18% | 0.55% |
#11
30
Prev: #41
|
3.9 | 980,470 | 133.7% |
P
S
|
1,714,000 | $170,954,360 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NBIX
NEUROCRINE BIOS...
|
Healthcare | 2.15% | 2.54% |
#12
3
Prev: #9
|
1.9 | no change | no change |
P
S
|
1,184,345 | $167,975,651 | 2000 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IONS
IONIS PHARMACEU...
|
Healthcare | 2.00% | 1.98% |
#13
2
Prev: #11
|
1.8 | no change | no change |
P
S
|
1,979,669 | $156,611,615 | 2016 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NAMS
NEWAMSTERDAM PH...
|
Healthcare | 1.87% | 1.85% |
#14
2
Prev: #12
|
1.2 | -101,904 | -2.4% |
P
S
|
4,164,789 | $146,100,798 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INSP
INSPIRE MED SYS...
|
Healthcare | 1.77% | 1.19% |
#15
11
Prev: #26
|
3.2 | 458,178 | 43.7% |
P
S
|
1,505,872 | $138,886,575 | 2018 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LEGN
LEGEND BIOTECH ...
|
Healthcare | 1.65% | 1.47% |
#16
3
Prev: #19
|
3.7 | 2,969,662 | 100.2% |
P
S
|
5,932,000 | $128,961,680 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BKD
BROOKDALE SR LI...
|
Healthcare | 1.60% | 1.51% |
#17
Prev: #17
|
1.1 | -4,610 | -0.0% |
P
S
|
11,637,032 | $125,563,575 | 2007 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INDV
INDIVIOR PLC
|
Healthcare | 1.55% | 2.57% |
#18
11
Prev: #7
|
0.6 | -3,593,748 | -51.4% |
P
S
|
3,393,063 | $121,743,100 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARWR
ARROWHEAD PHARM...
|
Healthcare | 1.55% | 0.52% |
#19
26
Prev: #45
|
3.6 | 839,946 | 84.6% |
P
S
|
1,832,946 | $121,689,285 | 2013 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LRMR
LARIMAR THERAPE...
|
Healthcare | 1.49% | 1.51% |
#20
4
Prev: #16
|
1.6 | no change | no change |
P
S
|
30,606,974 | $116,612,571 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CPRX
CATALYST PHARMA...
|
Healthcare | 1.46% | 1.50% |
#21
3
Prev: #18
|
1.1 | -63,606 | -1.3% |
P
S
|
4,911,161 | $114,626,498 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AHCO
ADAPTHEALTH COR...
|
Healthcare | 1.46% | 1.57% |
#22
7
Prev: #15
|
1.6 | no change | no change |
P
S
|
11,477,730 | $114,318,191 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCRX
BIOCRYST PHARMA...
|
Healthcare | 1.43% | 1.41% |
#23
3
Prev: #20
|
2.6 | 2,172,000 | 17.8% |
P
S
|
14,341,000 | $111,859,800 | 2005 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
IONIS PHARMACEU...
|
—
|
Bond/Debt | 1.22% | 1.26% |
#24
Prev: #24
|
1.5 | no change | no change |
P
S
|
60,000,000 | $95,328,000 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
N/A
ALIGNMENT HEALT...
|
—
|
Bond/Debt | 1.18% | — |
#25
Prev: #—
|
4.0 | 61,000,000 | no change |
NEW
|
61,000,000 | $92,553,470 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
SPRY
ARS PHARMACEUTI...
|
Healthcare | 1.12% | 1.15% |
#26
1
Prev: #27
|
1.4 | no change | no change |
P
S
|
7,503,812 | $87,419,410 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 1.11% | 0.93% |
#27
4
Prev: #31
|
2.9 | 683,578 | 28.0% |
P
S
|
3,126,042 | $86,747,666 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SVRA
SAVARA INC
|
Healthcare | 1.04% | 0.43% |
#28
24
Prev: #52
|
3.4 | 5,605,000 | 70.4% |
P
S
|
13,569,000 | $81,821,070 | 2018 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IDYA
IDEAYA BIOSCIEN...
|
Healthcare | 0.95% | 0.89% |
#29
4
Prev: #33
|
1.4 | no change | no change |
P
S
|
2,153,043 | $74,430,697 | 2019 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CERT
CERTARA INC
|
Healthcare | 0.88% | 1.26% |
#30
5
Prev: #25
|
2.4 | 1,069,068 | 15.9% |
P
S
|
7,808,605 | $68,793,810 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BIO
BIO RAD LABS IN...
|
Healthcare | 0.87% | 0.97% |
#31
2
Prev: #29
|
1.3 | no change | no change |
P
S
|
226,070 | $68,496,949 | 2003 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
NEOGENOMICS INC
|
—
|
Bond/Debt | 0.83% | 0.96% |
#32
2
Prev: #30
|
1.3 | no change | no change |
P
S
|
72,689,000 | $64,689,576 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
ACHC
ACADIA HEALTHCA...
|
Healthcare | 0.82% | 0.45% |
#33
17
Prev: #50
|
3.3 | 3,331,000 | 280.2% |
P
S
|
4,520,000 | $64,138,800 | 2017 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBOT
BRIDGEBIO ONCOL...
|
Healthcare | 0.78% | 0.86% |
#34
Prev: #34
|
1.3 | no change | no change |
P
S
|
4,885,446 | $61,165,784 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
STOK
STOKE THERAPEUT...
|
Healthcare | 0.74% | — |
#35
Prev: #—
|
3.8 | 1,823,500 | no change |
NEW
|
1,823,500 | $57,877,890 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LNTH
LANTHEUS HLDGS ...
|
Healthcare | 0.70% | — |
#36
Prev: #—
|
3.8 | 827,999 | no change |
NEW
|
827,999 | $55,103,333 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 0.68% | 0.16% |
#37
32
Prev: #69
|
3.3 | 394,586 | 105.7% |
P
S
|
767,993 | $53,413,913 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NVST
ENVISTA HOLDING...
|
Healthcare | 0.63% | 0.71% |
#38
3
Prev: #35
|
0.8 | -13,538 | -0.6% |
P
S
|
2,280,498 | $49,509,612 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EHAB
ENHABIT INC
|
Healthcare | 0.56% | 0.58% |
#39
1
Prev: #38
|
1.2 | no change | no change |
P
S
|
4,747,746 | $43,774,218 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 0.56% | 0.49% |
#40
7
Prev: #47
|
0.7 | -11,088 | -1.9% |
P
S
|
561,170 | $43,664,638 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDNA
CAREDX INC
|
Healthcare | 0.53% | 0.49% |
#41
7
Prev: #48
|
1.2 | no change | no change |
P
S
|
2,191,000 | $41,278,440 | 2014 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 0.52% | 0.93% |
#42
10
Prev: #32
|
0.2 | -408,240 | -44.4% |
P
S
|
511,163 | $40,591,454 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SION
SIONNA THERAPEU...
|
Healthcare | 0.51% | 0.44% |
#43
8
Prev: #51
|
1.2 | no change | no change |
P
S
|
970,590 | $39,930,073 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
LIVANOVA PLC
|
—
|
Bond/Debt | 0.51% | 0.56% |
#44
4
Prev: #40
|
1.2 | no change | no change |
P
S
|
34,280,000 | $39,725,721 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
BLTE
BELITE BIO INC
|
Healthcare | 0.48% | — |
#45
Prev: #—
|
3.7 | 233,813 | no change |
NEW
|
233,813 | $37,400,727 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DAWN
DAY ONE BIOPHAR...
|
Healthcare | 0.44% | 0.51% |
#46
Prev: #46
|
0.2 | -982,282 | -20.9% |
P
S
|
3,723,131 | $34,699,581 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHR
PHREESIA INC
|
Healthcare | 0.43% | 0.40% |
#47
8
Prev: #55
|
3.2 | 882,293 | 79.0% |
P
S
|
1,999,045 | $33,823,841 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EMBC
EMBECTA CORP
|
Healthcare | 0.42% | 0.56% |
#48
9
Prev: #39
|
2.2 | 131,610 | 5.0% |
P
S
|
2,752,031 | $32,694,128 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VCYT
VERACYTE INC
|
Healthcare | 0.39% | 0.38% |
#49
8
Prev: #57
|
1.2 | no change | no change |
P
S
|
726,000 | $30,564,600 | 2015 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRNA
PUT
MODERNA INC
|
PUT Option | 0.38% | 0.39% |
#50
6
Prev: #56
|
1.2 | no change | no change |
P
S
|
1,000,000 | $29,490,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 184 holdings